131 RichardsG
Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B, Rotkvic I, Mise S, Zoricic I, Konjevoda P, Perovic D, Simicevic V, Separovic J, Hanzevacki M, Ljubanovic D, Artukovic B, Bratulic M, Tisljar M, Rekic B, Gjurasin M, Miklic P, Buljat G
What Patients Need to Know in 2026 If youve looked into starting a GLP-1 medication, you may already know how complicated the question of insurance coverage is
I dont want to dive too deep on these pathways but regardless these provide further anti-inflammatory benefits along with basically telling your cells to get rid of your garbage, so it doesnt cause problems
Novo said last week that CagriSema was "well-tolerated" and that the most common adverse effects were gastrointestinal, but they were "mild to moderate and diminished over time." "Investors are looking for treatment options that are best in class and will secure Novo's place in the obesity drug market," Soren Lontoft, pharma equity analyst at Sydbank, told CNBC over the phone Tuesday